The Biostatistics and Bioinformatics Core B will provide statistics and bioinformatics support and expertise in experimental design, data analysis and interpretation ofthe results as needed by the Projects and other Cores to achieve their Specific Aims. The studies in this POl require a variety of statistical and bioinformatic data analysis strategies such as modeling time course experiment data, tesfing synergisfic effect of kinase inhibitor combination, and analyzing genomic profiling data of RNA expression and DNA copy number. In addition. Core B will develop and maintain a bioinformatics infrastructure to enable collaboration and data sharing among research projects. This infrastructure includes: 1) a gene signature database 2) a somafic mutation database and functional characterization tools, and 3) a virtual cell line repository. A broad range of bioinformatics, computational, and statistical techniques will be applied to create this infrastructure.

Public Health Relevance

The Biostatistics and Bioinformatics Core B forms an integral part ofthe P01 and will provide services that are essential for many of the different projects within the POl, assisting the POl investigators in their achievement of the overall research objective: developing new targets for therapy for carcinomas of the lung.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA129243-08
Application #
8720711
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
8
Fiscal Year
2014
Total Cost
$133,013
Indirect Cost
$46,027
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Chen, Qing; Boire, Adrienne; Jin, Xin et al. (2016) Carcinoma-astrocyte gap junctions promote brain metastasis by cGAMP transfer. Nature 533:493-8
Hames, Megan L; Chen, Heidi; Iams, Wade et al. (2016) Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer☆. Lung Cancer 92:29-34
Amato, Katherine R; Wang, Shan; Tan, Li et al. (2016) EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer. Cancer Res 76:305-18
Lito, Piro; Solomon, Martha; Li, Lian-Sheng et al. (2016) Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism. Science 351:604-8
Malladi, Srinivas; Macalinao, Danilo G; Jin, Xin et al. (2016) Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell 165:45-60
Konduri, Kartik; Gallant, Jean-Nicolas; Chae, Young Kwang et al. (2016) EGFR Fusions as Novel Therapeutic Targets in Lung Cancer. Cancer Discov 6:601-11
Dragani, Tommaso A; Castells, Antoni; Kulasingam, Vathany et al. (2016) Major milestones in translational oncology. BMC Med 14:110
Manchado, Eusebio; Weissmueller, Susann; Morris 4th, John P et al. (2016) A combinatorial strategy for treating KRAS-mutant lung cancer. Nature 534:647-51
Johnson, Douglas B; Estrada, Monica V; Salgado, Roberto et al. (2016) Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat Commun 7:10582
Massagué, Joan; Obenauf, Anna C (2016) Metastatic colonization by circulating tumour cells. Nature 529:298-306

Showing the most recent 10 out of 157 publications